Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2018-04-16 Regulatory Filings
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a new product launch (HEBELYS®) resulting from a collaboration between two companies (DEINOVE and GREENTECH). It details the product's features, testing results, and upcoming presentation at a trade show. This format—a formal announcement of business news, product development, or partnership—is characteristic of a general press release. Since there is no specific regulatory filing code (like 10-K, ER, or DIV) associated with this content, and it is not a report itself but an announcement of a business event/product, the most appropriate general category is 'Regulatory Filings' (RNS), which serves as a fallback for miscellaneous regulatory or corporate announcements that don't fit the highly specific categories, or potentially 'Report Publication Announcement' (RPA) if it were announcing the release of a formal report, but here it announces a product launch and presentation. Given the nature of a press release announcing a new commercial product and partnership, RNS is the best fit as a general corporate announcement/filing.
2018-04-16 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 1% confidence The document is a press release ("Communiqué de presse") dated April 13, 2018, announcing a significant corporate action: DEINOVE's acquisition of BIOVERTIS/MORPHOCHEM via an in-kind contribution ("opération d'apport en nature"). This transaction involves the transfer of an antibiotic compound (MCB3837) and results in new shareholders (TVM Capital) joining DEINOVE's capital. The text details the terms of the capital increase, the issuance of shares and warrants (BAA), and mentions a future General Assembly approval date (May 23, 2018). This type of announcement, detailing fundraising, capital structure changes, and major corporate transactions involving share issuance, aligns best with the 'Capital/Financing Update' category. It is not a standard regulatory report (10-K, IR, ER) but a specific corporate announcement about financing/capital structure change (CAP). It is not a simple announcement of a report (RPA/RNS) because it contains substantial details about the transaction itself, not just a notice that a report is available.
2018-04-13 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Capital/Financing Update Classification · 1% confidence The document announces the acquisition by DEINOVE of MORPHOCHEM's clinical-stage antibiotic compound (MCB3837) via a contribution-in-kind transaction involving BIOVERTIS. It details the terms of the transaction, including share issuance, warrants, and future financing commitments. This content describes a significant corporate action related to financing, capital structure, and asset acquisition, which falls under the scope of Capital/Financing Update (CAP). It is not a standard periodic report (10-K, IR), an earnings release (ER), or a management discussion (MDA). The mention of TVM Capital becoming a shareholder and the commitment to future financing strongly supports the CAP classification.
2018-04-13 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces the official launch of a new cosmetic active ingredient, Phyt-N-Resist®, developed by DEINOVE. It details the product's properties, scientific basis (biotechnology/fermentation), clinical test results, and plans to present it at an industry trade show (In-cosmetics Global). This type of announcement, focused on a specific product launch or significant business development communicated via a press release, does not fit the definitions for formal regulatory filings (10-K, IR, ER, etc.) or specific shareholder communications (DEF 14A, DVA). Since it is a general business announcement detailing a new product/innovation, it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure, although it is not a standard SEC/exchange filing. Given the options, RNS serves as the best general disclosure category for non-standard, non-financial-period-specific announcements like product launches, especially when the content is not a transcript (CT) or a management discussion (MDA). It is not short enough to be strictly an RPA, as it contains substantial detail about the science and results.
2018-04-10 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated April 10, 2018, announcing the launch of a new cosmetic active ingredient called PHYT-N-RESIST® (pure Phytoene) developed by DEINOVE using bacterial fermentation. It details the product's properties, clinical test results, and plans to showcase it at an industry event. This is a commercial announcement detailing a new product launch and its associated scientific/market information, rather than a mandatory regulatory filing like a 10-K, an earnings release (ER), or a formal investor presentation (IP). Since it is a press release announcing a new product/development, it fits best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement that doesn't fit the more specific financial or governance codes. It is not a Call Transcript (CT), Earnings Release (ER), or a formal Investor Presentation (IP). Given the options, RNS serves as the best general announcement category for non-standard corporate news releases.
2018-04-10 English
Rapport financier annuel
Annual Report Classification · 1% confidence The document is titled 'Rapport financier annuel 2017' (Annual Financial Report 2017) for Groupe DEINOVE. It contains a comprehensive summary including the management report, corporate governance, consolidated financial statements (balance sheet, income statement, cash flow), and the auditor's report. It is a full-length annual financial report, not an announcement or a summary, and thus fits the definition of an Annual Report (10-K). FY 2017
2018-03-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.